Dose Optimization of Caffeine for HIE
Part of paid clinical trials in Chapel Hill, North Carolina.
- Sponsor
- University of North Carolina, Chapel Hill
- Study ID
- NCT06448780
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Hypoxic-Ischemic Encephalopathy
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 24 Hours
- Healthy Volunteers
- Not accepted
Interventions
- Caffeine citrate 20 mg/kg — DRUGFollowing loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
- Caffeine citrate 30 mg/kg — DRUGFollowing loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Study Details
This is a phase Ib, open-label, dose-validating and safety study of caffeine in neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia.
Key Dates
- Start date
- Jul 26, 2024
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2026
- Completion
- Nov 30, 2028
Study Design
- Enrollment
- 16 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Lower loading dose (20 mg/kg)Within 24 hours after delivery, participants will receive a loading dose of 20 mg/kg caffeine citrate IV.
- Active Comparator: Higher loading dose (30 mg/kg)Within 24 hours after delivery, participants will receive a loading dose of 30 mg/kg caffeine citrate IV.
Primary Outcome Measure
Apparent Caffeine Clearance [ Time Frame: 7 samples will be collected after the first dose of study drug and up to 72 hours after final dose of study drug ]
Central Contacts
- Wesley M Jackson, MD, MPH984-215-3449
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of North Carolina at Chapel Hill Newborn Critical Care Center | Chapel Hill | North Carolina | 27599 | |
| Novant Health New Hanover Regional Medical Center | Wilmington | North Carolina | 28401 |
Find similar trials in Chapel Hill, NC
Related Studies
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic HypothermiaPHASE2 · Recruiting · ReAlta Life Sciences, Inc. · Little Rock, Arkansas
- Florida Neonatal Neurologic NetworkEnrolling By Invitation · University of Florida · Gainesville, Florida
- Systemic Biomarkers of Brain Injury From HyperammonemiaRecruiting · Children's National Research Institute · Washington D.C., District of Columbia
- Spinal Stimulation and Mobility DevicesRecruiting · University of Washington · Seattle, Washington